Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) on January 11, it was announced that it would jointly promote AI drug research and development of multiple targets worldwide with end-to-end AI driven drug research and development company insilico medicine, including AI driven drug research and development cooperation for four designated targets, joint development cooperation of insilico intelligent qpctl project, etc.
According to the cooperation agreement, ISI is responsible for nominating preclinical candidate drugs for qpctl project, promoting the candidate drugs to preclinical stage, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) carrying out clinical stage research on them, and jointly promoting the development of the project worldwide. Meanwhile, the R & D team of Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) will nominate four targets to be evaluated and developed by the artificial intelligence platform and R & D team of silicon intelligence, and promote the candidate drugs to the preclinical stage.
As part of the cooperation, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) will obtain the right to use the industrial silicon intelligent artificial intelligence platforms pandaomics and chemisty42 to promote the company’s internal artificial intelligence driven drug discovery and development.
In this cooperation, Anglo silicon intelligence will receive a down payment and milestone payment of US $13 million, and share the commercialization profits of qpctl project. In addition, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) will provide equity investment to yingsi intelligence. The two sides said that this cooperation will improve the R & D efficiency of innovative drugs and open a new era of end-to-end drug discovery enabled by artificial intelligence. Man machine cooperation is becoming a new normal for precision drug R & D.
(source: Beijing News)
